Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune response
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The dual erb B 1/2 tyrosine kinase inhibitor lapatinib as well as the anthracycline doxorubicin are both used in the therapy of HER 2‐positive breast cancer. Using MMTV‐neu mice as an animal model for HER 2‐positive breast cancer, we observed enhanced tumor infiltration by IFN‐γ‐secreting T cells after treatment with doxorubicin and/or lapatinib. Antibody depletion experiments revealed a contribution of CD 8+ but not CD 4+ T cells to the antitumor effect of these drugs. Doxorubicin treatment additionally decreased the content of immunosuppressive tumor‐associated macrophages (TAM s) in the tumor bed. In contrast, S tat1‐deficient mice were resistant to tumor growth inhibition by lapatinib and/or doxorubicin and exhibited impaired T‐cell activation and reduced T‐cell infiltration of the tumor in response to drug treatment. Furthermore, S tat1‐deficiency resulted in reduced expression of the T‐cell chemotactic factors CXCL 9, CXCL 10, and CXCL 11 in the tumor epithelium. The inhibition of TAM infiltration of the tumor by doxorubicin and the immunosuppressive function of TAM s were found to be S tat1 independent. Taken together, the results point to an important contribution toward enhancing T‐cell and IFN‐γ‐based immunity by lapatinib as well as doxorubicin and emphasize the role of S tat1 in building an effective antitumor immune response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Tanizaki, J., Okamoto, I., Fumita, S., Okamoto, W., Nishio, K., & Nakagawa, K. (2011) · Oncogene · doi:10.1038/onc.2011.111 · Cited by 70
Cited by
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,358
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Metadata
- Authors
- Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., Müller‐Holzner, E., Wiegers, G. J., Sexl, V., Villunger, A., & Doppler, W.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2013-07-11
- Volume
- 43
- Issue
- 10
- Pages
- 2718-2729
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1546466517
- Cited by
- 113
- References
- 7
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune response. https://app.cochat.ai/papers/10.1002/eji.201242505
- The paper
- Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., Müller‐Holzner, E., Wiegers, G. J., Sexl, V., Villunger, A., & Doppler, W. (2013). Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune response. European Journal of Immunology. https://doi.org/10.1002/eji.201242505
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.